Fisher and Nanogen Will Share IP, Technologies to Co-Develop Molecular Dxs
 
Nanogen and Fisher Scientific International last week said they will share each other's technology and patent rights in order to develop, manufacture, and market new molecular diagnostic products.
 
As part of the deal, Fisher “may provide” Nanogen up to $10 million during 2007 and 2008 to research and develop infectious disease and molecular diagnostic tests “that will be mutually agreed upon.”
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.